Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06040593 · ClinicalTrials.gov registry record
Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
A clinical trial, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- 927
- Enrollment target
NCT06040593: Completed study, sponsored by Daiichi Sankyo.
NCT06040593 is a clinical trial that has completed, run by Daiichi Sankyo. The registered enrollment target is 927 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06040593 has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- 927 participants
- Enrollment target
Study Summary
There is a lack of data on clinical and patient factors that are associated with poor survival in patients with HR+ and HER2-low/negative breast cancer treated with neoadjuvant chemotherapy or endocrine therapy. This retrospective, non-interventional study is designed to assess the predictors of clinical outcomes in this patient population. No study drug will be provided as part of this study protocol.
Primary Outcome
Events of interest include any other primary cancer, metastases, higher stage, tumor progression, and death due to any cause.
Interventions
- OTHER No drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 927 participants |
| Start Date | 2023-07-31 |
| Est. Completion | 2024-02-23 |
What the finished NCT06040593 record still lists
NCT06040593 is an observational study that tracks outcomes without assigning an intervention. The registered 927 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which No drug is the first listed.
NCT06040593 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06040593 about?
NCT06040593 is a clinical study titled "Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer". There is a lack of data on clinical and patient factors that are associated with poor survival in patients with HR+ and HER2-low/negative breast cancer treated with neoadjuvant chemotherapy or endocrine therapy. This retrospective, non-interventional study is designed to assess the predictors of cli...
What is the current status of trial NCT06040593?
This trial is currently completed. The enrollment target is 927 participants. The study started on 2023-07-31. Estimated completion is 2024-02-23.
What interventions are being tested in trial NCT06040593?
The interventions under investigation include: No drug (OTHER).
Who is sponsoring clinical trial NCT06040593?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06378541 · 928 participants · NA
Smartphone App Enhanced Facilitation Among Veterans in a Mental Health Inpatient Setting (Project HOPE)
- NCT06555029 · 929 participants · NA
Oral Health Intervention in Adult Primary Care
- NCT03995082 · 925 participants · NA
Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey
- NCT05216432 · 930 participants · Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI